{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-094848","form_type":"8-K","ticker":"OTLK","cik":"0001649989","company_name":"Outlook Therapeutics, Inc.","filed_at":"2026-08-12T20:01:42+00:00","discovered_at":"2026-08-12T20:03:17.826645+00:00","generated_at":"2026-08-12T20:03:36.640288+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Outlook Therapeutics reports $11.2M cash; going concern doubt persists","bullets":["Preliminary cash and cash equivalents of $11.2M as of June 30, 2026 (unaudited).","Net loss of $62.4M in FY2025; revenue of $1.4M from LYTENAVA sales in Germany/UK.","Going concern: cash only sufficient into September 2026; need substantial additional capital.","$19.8M outstanding under Atlas Sciences note due June 2027; 7.5% exit fee on redemptions.","Terminated ATM prospectus supplement with H.C. Wainwright on Aug 10, 2026; agreement remains."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-094848","json":"https://secwatch.observer/filing/0001104659-26-094848.json","markdown":"https://secwatch.observer/filing/0001104659-26-094848.md","text":"https://secwatch.observer/filing/0001104659-26-094848.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1649989/000110465926094848/0001104659-26-094848-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1649989/000110465926094848/tm2622278d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-12T20:03:36.640288+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}